DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients
Moreau, Manon (Université Paris Cité)
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau)
Altuna-Azkargorta, Miren (Institut d'Investigació Biomèdica Sant Pau)
Dalzon, Lorraine (Université Paris Cité)
Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau)
Vilaire, Marie (Institut Médical Jérôme Lejeune)
Durand, Sophie (Institut Médical Jérôme Lejeune)
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau)
Rebillat, Anne-Sophie (Institut Médical Jérôme Lejeune)
Janel, Nathalie (Université Paris Cité)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Down syndrome (DS) is a complex genetic condition due to an additional copy of human chromosome 21, which results in the deregulation of many genes. In addition to the intellectual disability associated with DS, adults with DS also have an ultrahigh risk of developing early onset Alzheimer's disease dementia. DYRK1A, a proline-directed serine/threonine kinase, whose gene is located on chromosome 21, has recently emerged as a promising plasma biomarker in patients with sporadic Alzheimer's disease (AD). The protein DYRK1A is truncated in symptomatic AD, the increased truncated form being associated with a decrease in the level of full-length form. Activity-dependent neuroprotective protein (ADNP), a key protein for the brain development, has been demonstrated to be a useful marker for symptomatic AD and disease progression. In this study, we evaluated DYRK1A and ADNP in CSF and plasma of adults with DS and explored the relationship between these proteins. We used mice models to evaluate the effect of DYRK1A overexpression on ADNP levels and then performed a dual-center cross-sectional human study in adults with DS in Barcelona (Spain) and Paris (France). Both cohorts included adults with DS at different stages of the continuum of AD: asymptomatic AD (aDS), prodromal AD (pDS), and AD dementia (dDS). Non-trisomic controls and patients with sporadic AD dementia were included for comparison. Full-form levels of DYRK1A were decreased in plasma and CSF in adults with DS and symptomatic AD (pDS and dDS) compared to aDS, and in patients with sporadic AD compared to controls. On the contrary, the truncated form of DYRK1A was found to increase both in CSF and plasma in adults with DS and symptomatic AD and in patients with sporadic AD with respect to aDS and controls. ADNP levels showed a more complex structure. ADNP levels increased in aDS groups vs. controls, in agreement with the increase in levels found in the brains of mice overexpressing DYRK1A. However, symptomatic individuals had lower levels than aDS individuals. Our results show that the comparison between full-length and truncated-form levels of DYRK1A coupled with ADNP levels could be used in trials targeting pathophysiological mechanisms of dementia in individuals with DS.
Ajuts:	Instituto de Salud Carlos III PI17/01019 Instituto de Salud Carlos III PI20/01473 Instituto de Salud Carlos III PI18/00335
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	ADNP ; Alzheimer's disease ; Brain ; CSF ; Down syndrome ; DYRK1A ; Plasma
Publicat a:	Biomedicines, Vol. 10 (june 2022) , ISSN 2227-9059

DOI: 10.3390/biomedicines10061380
PMID: 35740400

11 p, 708.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats